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ABSTRACT
Background: Tobacco use is a major risk factor for
recurrent stroke. The provision of cost-free quit
smoking medications has been shown to be
efﬁcacious in increasing smoking abstinence in the
general population.
Objective: The objective of this pilot study was to
assess the feasibility and obtain preliminary data on
the effectiveness of providing cost-free quit smoking
pharmacotherapy and counselling to smokers
identiﬁed in a stroke prevention clinic.
Trial design: Cluster randomised controlled trial.
Methods: All patients seen at the Ottawa Hospital
Stroke Prevention Clinic who smoked more ﬁve or
more cigarettes per day, were ready to quit smoking in
the next 30 days, and were willing to use
pharmacotherapy were invited to participate in the
study. All participants were advised to quit smoking
and treated using a standardised protocol including
counselling and pharmacotherapy. Participants were
randomly assigned to either a prescription only usual
care group or an experimental group who received
a 4-week supply of cost-free quit smoking medications
and a prescription for medication renewal. All patients
received follow-up counselling. The primary outcome
was biochemically validated quit rates at 26 weeks.
The research coordinator conducting outcome
assessment was blind to group allocation.
Results: Of 219 smokers screened, 73 were eligible,
28 consented and were randomised, and 25 completed
the 26-week follow-up assessment. All 28 patients
randomised were included in the analysis. The
biochemically validated 7-day point prevalence
abstinence rate in the experimental group compared to
the usual care group was 26.6% vs 15.4% (adjusted
OR 2.00, 95% CI 0.33 to 13.26; p¼0.20).
Conclusions: It would be feasible to deﬁnitively
evaluate this intervention in a large multi-site trial.
Trial registration number: http://ClinicalTrials.gov #
UOHI2010-1.
INTRODUCTION
Cigarette smoking is a major independent
risk factor for recurrent stroke and has been
identiﬁed as an important treatment target
for all patients at high risk of future
stroke.
1e4 Stroke and transient ischaemic
attack (TIA) patients who quit smoking
reduce their relative risk of stroke recurrence
by 50%.
5 Smoking cessation is also associated
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Unfortunately, most smokers with cerebrovascular
disease have difﬁculty quitting on their own. Previous
research has documented that approximately 80e90%
of stroke and TIA patients identiﬁed as smokers at the
time of their event continued to use tobacco 6e12
months later.
8e10
Evidence from placebo-controlled clinical trials
consistently demonstrates that cessation medications
such as nicotine replacement therapy, bupropion and
varenicline combined with counselling, can double or
triple long-term smoking abstinence in smokers.
11e13
Consequently, stroke prevention guidelines recommend
that healthcare providers strongly advise every smoker
who is at high risk for a stroke or TIA to quit, and
provide speciﬁc assistance with quitting, including
counselling and pharmacotherapy.
14 15 Despite the
evidence supporting the importance of smoking cessa-
tion, there is a well documented practice gap in the rates
at which smoking cessation is addressed by healthcare
professionals, even for high risk groups such as TIA
patients and/or stroke survivors.
8e10
Sub-optimal use of evidence-based quit smoking
medications and premature discontinuation of pharma-
cotherapy has been linked to poorer rates of smoking
abstinence.
16 17 Although reasons for poor adherence
are varied, ﬁnancial barriers are a major determinant for
non-use and non-adherence.
18 19 The provision of cost-
free medications has been shown to improve motivation
to quit and increase quit attempts and smoking absti-
nence in the general population; no study, however, has
examined the efﬁcacy of providing cost-free cessation
pharmacotherapy to patients who have recently experi-
enced a TIA or stroke or are at high risk for stroke.
20e23
Given that a high incidence of stroke has been
reported among lower socioeconomic groups, it is
hypothesised that making cost-free medications available
to patients who receive standardised smoking cessation
interventions will enhance patient quit attempts, remove
barriers related to the cost of pharmacotherapy, and
enhance compliance with the full course of pharmaco-
therapy among patients and lead to increased success
with quitting.
24 25 The low quit rates documented among
patients who have experienced TIA or stroke, supports
the need to determine the efﬁcacy of interventions
which may enhance cessation in this high risk group of
smokers.
8e10 Moreover, the high risk of a recurrent event
among stroke patients who continue to smoke suggests
the cost-beneﬁt of providing cost-free pharmacotherapy
may be realised in a relatively short time frame, which
may justify providing coverage to this group of high risk
smokers.
6 As such, the purpose of this pilot study was to
test feasibility and obtain effect estimates to inform the
design of a larger deﬁnitive study on the effectiveness of
providing cost-free quit smoking pharmacotherapy and
counselling to smokers identiﬁed in a specialty stroke
prevention clinic compared to the provision of
a conventional prescription for pharmacotherapy.
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METHODS
Design
This pilot study was a two-group, open label, experi-
mental feasibility study with random assignment to
either a prescription-only usual care group (PO group)
or a cost-free quit smoking medications group (CF
group). The primary outcome was biochemically vali-
dated quit rates at 26 weeks. Secondary outcome
measures included patient quit attempts at 26 weeks and
adherence to quit smoking counselling and pharmaco-
therapy protocols. Levels of eligibility, consent, adher-
ence and retention were used as indicators of study
feasibility. The study protocol was approved by the
University of Ottawa Heart Institute Human Research
Ethics Board.
Setting and patient population
Patients were recruited from The Ottawa Hospital Stroke
Prevention Clinic, Ottawa, Ontario, Canada over an 18-
month period. The clinic provides assessment and
secondary prevention services to patients who have
recently experienced a TIA or stroke or have been iden-
tiﬁed as being at high risk for a cerebrovascular event.
Sample size
It was estimated that a total of 70 patients would be
enrolled over the 18-month recruitment period based on
the assumption that 200 smokers were seen at the clinic
in the previous year and 25% were estimated to be
eligible and willing to participate. It was hypothesised
that a 5e10% increase in smoking abstinence would be
documented in the CF group compared to the PS group
based on trials in the general population.
20e23 It was
understood that the trial would not be powered to detect
signiﬁcant differences between groups.
Standardised smoking cessation protocol
As part of the study, a systematic approach to the iden-
tiﬁcation and treatment of patients who smoke was
introduced into routine clinic practice at the Stroke
Prevention Clinic; the protocol was based on the Ottawa
Model for Smoking Cessation.
27 28 The nurse specialists
and neurologists providing care in this setting were
provided with training sessions in evidence-based
smoking cessation interventions. Patient and provider
tools and resources, adapted from the Ottawa Model for
Smoking Cessation, were introduced in the stroke clinic
to facilitate and support the standardised delivery of
tobacco treatment. This included a waiting room
screening form, a consult form to support clinicians in
the delivery of cessation interventions, and a quit plan
for patients ready to quit smoking.
The waiting room screening form which assessed
current smoking status was distributed to all patients
upon registration at the clinic. Patients were instructed
to return the screening form to the clerk when
completed. The screening nurse used the results
obtained in the screening process to ﬂag all patient
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non-smoker. A smoking cessation consult form was
placed on the chart of each patient identiﬁed as
a smoker by the clerk and served as a prompt to the
neurologist for delivering evidence-based smoking
cessation interventions. The neurologist then provided
strong, unambiguous, non-judgemental advice to quit to
all smokers along with an offer of support with making
a cessation attempt. The neurologist also assessed
patient readiness to quit in the next 30 days and
documented patient response on the consult form.
Eligibility screening
Patients were eligible to participate in the study if they
reported smoking an average of ﬁve or more cigarettes
per day in the past 3 months, were 18 years of age or
older, were willing to set a quit date in the next 30 days,
and were willing to use a quit smoking medication.
Patients who were unable to read and understand
English or French or who had contraindications to all
approved smoking cessation medications (nicotine
replacement therapy, bupropion and varenicline) were
excluded from the study. Eligible patients were invited
by the neurologist or the stroke prevention nurse
specialist to take part in the study. Eligible patients
interested in participating in the study had the
study procedures explained to them by the research
study coordinator. All participants provided informed
consent.
Allocation to treatment
Patients were randomly assigned to one of two inter-
vention groups. The research coordinator or clinic nurse
specialist opened a sealed envelope which contained the
treatment group allocation. Randomisation envelopes
were prepared by a third party using a random numbers
table blocked in groups of four and sealed until treat-
ment allocation. Due to the nature of the intervention,
participants and clinicians were not blinded to their
intervention assignment.
Comparison groups
Cost-free pharmacotherapy experimental group (CF group)
Participants assigned to the CF group received a starter
kit (4-week supply) of cost-free quit smoking medication
(nicotine replacement therapy, bupropion or vareni-
cline) and a pre-printed prescription to be ﬁlled by the
patient at the end of the 4 weeks.
Prescription only usual care group (PO group)
Participants assigned to the prescription only usual care
group received a prescription for smoking cessation
pharmacotherapy to be ﬁlled at their own cost at their
local community pharmacy.
Patient quit plan consultation and telephone follow-up
support
The stroke prevention nurse specialist conducted
a1 0 e20 min consultation with all study participants
using a standardised consult form and patient education
materials. During the consult discussion, the nurse
specialist addressed patient concerns about quitting, set
a target quit date (TQD) with the patient in the next
30 days, developed strategies for addressing cravings and
withdrawal, and identiﬁed strategies for relapse preven-
tion and management. Patients were then prescribed
a ﬁrst-line quit smoking pharmacotherapy. The choice of
the pharmacotherapy was based on patient preference
and smoking history. All study participants were
contacted by phone by a trained smoking cessation
counsellor 7 days before their TQD, and 5, 14, 30, 90
and 180 days after to discuss the patient’s quit smoking
progress, address potential concerns and assist with
relapse prevention strategies and management. During
the call, the smoking cessation nurse specialist posed
a series of questions concerning: current smoking status;
conﬁdence in staying smoke-free until the next planned
call; and the use of pharmacotherapy, self-help materials
and other forms of cessation support.
Post-assessment and follow-up data collection
All participants were contacted by telephone 26 weeks
(62 weeks) after their TQD to assess outcome measures.
All patients reporting smoking abstinence had an end-
expired carbon monoxide (CO) sample collected in
order to validate smoking abstinence.
Outcome measures
The dependent variables of primary interest were
measured at 26 weeks and included: (1) biochemically
conﬁrmed 7-day point prevalence abstinence; and (2)
continuous abstinence since TQD. Participants who were
not available for follow-up were considered smokers. At
the 26-week follow-up, all patients who reported being
abstinent from smoking had their smoking status
conﬁrmed by measurement of a CO sample. If any CO
was >10 ppm, the subject was considered a smoker. At
the 26-week follow-up assessments, patient quit attempts
in the previous 6 months of 24 h or longer were docu-
mented. During the 26-week telephone follow-up
assessment, patient adherence with pharmacotherapy
was assessed by evaluating the number of doses of
pharmacotherapy consumed within the prescribed study
interval. The telephone counsellor recorded the
completion of all seven counselling sessions in order to
assess patient adherence.
Analysis
Descriptive characteristics were assessed for all smokers
screened at the stroke prevention clinic during the
recruitment period. Baseline characteristics of study
participants assigned to each of the intervention groups
were compared using independent t tests for continuous
variables and c
2 tests for categorical variables to assess
any chance imbalances that may have occurred. A
logistic regression model was ﬁtted to 26-week absti-
nence status (smoker or non-smoker) and treatment
group included as the independent variable. Adjusted
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ences between groups. Treatment adherence and patient
quit attempts were also compared between treatment
groups. All patients were included in the intention to
treat analysis. Missing data were categorised as active
smoking (smoking abstinence), not having made
a quit attempt (quit attempts) or non-compliant with
medications (adherence).
RESULTS
Participant recruitment and data collection
Figure 1 presents the CONSORT diagram for data
collection ﬂow. There were 2182 patient visits at the
Stroke Prevention Clinic between August 2008 and
December 2009 and 219 unique patients were identiﬁed
as having used tobacco in the last 7 days. Table 1
provides a summary of the characteristics of all patients
screened at the Stroke Prevention Clinic who reported
active smoking during the study recruitment period. At
the initial screening, 74% of smokers reported they were
planning on quitting smoking within the next 6 months
and 36% were planning on quitting in the next 30 days.
A total of 147 patients who smoked did not meet eligi-
bility criteria. The primary reason for exclusion was the
patient not being willing to quit smoking in the next
30 days and smoking less than an average of ﬁve ciga-
rettes per day. An additional 14 patients were not willing
to use pharmacotherapy. Among eligible patients, 29/73
(40%) agreed to participate in the study. Study partici-
pants were more likely than non-participants to be
younger, to smoke more cigarettes per day, and to be
concerned about withdrawal and stress, and less
concerned about boredom. Two study participants
withdrew from the study. The 26-week follow-up data
were complete for 25/28 (89%) study participants.
There were no signiﬁcant differences in loss to follow-up
between intervention groups.
Participant characteristics
A total of 28 eligible smokers (mean age
54.5610.5 years, 70% male) were enrolled in the pilot
study. The characteristics of study participants are
presented in table 1. CF participants reported smoking
signiﬁcantly more cigarettes per day as well as signiﬁ-
cantly greater self-efﬁcacy (conﬁdence) with quitting
compared to participants randomised to the PO group.
Smoking abstinence
Table 2 presents the effect estimates for smoking
abstinence. Quit rates were 33.3% in the CF group
versus 15.4% in the PO group for 7-day point pre-
valence abstinence and 23.1% compared to 15.4%
for continuous abstinence at 26 weeks. Effect estimates
were adjusted to account for the observed differences
between groups. The adjusted OR for self-reported
continuous abstinence was 5.51 (95% CI 0.44 to 69.3;
p¼0.186) and 7-day point prevalence abstinence
w a s2 . 2 5( 9 5 %C I0 . 2 5t o2 0 . 4 ;p ¼0.470). Observed
differences between groups were not statistically
signiﬁcant.
Figure 1 CONSORT
(Consolidated Standards of
Reporting Trials) diagram.
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nence was reported for 75% of patients who declared
a smoke-free status at the end of 26 weeks. No differences
were noted in the rates of completion of the biochemical
validation at the pre- and post-intervention assessments
nor were differences noted between CF and PO inter-
vention groups (26.6% vs 15.4%). The adjusted OR for
biochemically validated 7-day point prevalence absti-
nence was 5.95 (95% CI 0.40 to 88.7; p¼0.195). Observed
differences between groups were not signiﬁcant.
Table 1 Characteristics of smokers screened and study participants
Parameter
Smokers
screened
(n[219)
Eligible
non-participants
(n[44)
Study
participants
(n[28)
PO group
(n[13)
CF group
(n[15) p Value*
Age, mean (SD) 55.4 (12.8) 59.4 (9.8) 54.5 (10.5) 53.5 (8.1) 55.4
(12.4)
0.65
% Male 48.8 61.4 60.7 69.2 53.3 0.39
Years of education,
mean (SD)
12.1 (3.1) 11.6 (4.2) 11.7 (3.4) 12.9 (2.3) 10.6 (4.0) 0.08
Cigarettes/day,
mean (SD)
15.1 (10.4) 16.9 (10.6) 17.5 (8.0) 20.7 (8.8) 14.8 (6.2) 0.05
Years smoking
cigarettes, mean (SD)
33.3 (15.0) 34.7 (13.6) 34.6 (14.5) 32.5
(15.1)
36.4
(14.1)
0.49
Time to ﬁrst cigarette
% Within 30 min of
waking
67.3 72.2 78.5 77.0 80.0 0.87
% More than 30 min
after waking
32.7 27.8 21.5 23.0 20.0
Conﬁdence (SD)y 5.4 (3.3) 6.1 (3.4) 6.2 (3.1) 5.0 (3.2) 7.3 (2.6) 0.05
Importance of
quitting (SD)z
7.2 (3.3) 7.5 (3.2) 8.3 (2.4) 8.6 (2.7) 7.9 (2.3) 0.47
Quit attempts
None 41.3 53.2 35.7 30.8 40.0 0.78
1 or 2 36.0 18.4 39.3 46.2 33.3
3 or more 22.7 26.3 25.0 23.1 26.7
Readiness to quit at initial screeningx
Next 30 days 40.4 54.5 70.4 84.6 57.1 0.12
Next 6 months 59.6 45.5 29.6 15.4 42.9
Other smoker in the home 45.3 51.3 46.4 53.8 40.0 0.35
Medication coverage
Yes 18.2 15.9 32.1 38.5 26.7 0.62
No 49.4 45.4 32.1 23.1 40.0
Don’t know 32.4 38.7 35.7 38.5 33.3
HADS score{
Anxiety, mean (SD) ee 7.0 (3.8) 6.8 (3.8) 7.1 (3.9) 0.88
Depression, mean (SD) ee 5.1 (4.1) 5.5 (2.8) 4.7 (4.9) 0.64
Reasons for quitting
Health reasons 81.9 77.8 93.1 92.3 93.8 0.88
Family 20.6 16.7 34.5 38.5 31.3 0.68
Financial 20.5 19.4 20.7 23.1 18.8 0.78
Social 11.9 11.4 13.8 15.4 12.5 0.82
Concerns about quitting
Stress 53.3 43.2 62.1 46.2 75.0 0.11
Withdrawal 35.3 38.6 48.3 53.8 43.8 0.59
Weight 29.4 25.0 37.9 38.5 37.5 0.96
Boredom 18.2 13.6 24.1 23.1 25.0 0.90
Social 9.6 9.1 3.4 0.0 6.3 0.36
*Comparisons are based on the Pearson c
2 test for categorical variables and Student t test for continuous variables between intervention
groups.
yOn a scale of 1e10, how conﬁdent are you that you would be able to quit smoking at this time? (1¼not at all conﬁdent, 10¼extremely
conﬁdent).
zOn a scale of 1e10, how important is it to you to quit smoking at this time? (1¼not important at all, 10¼extremely important).
xResponse provided on the waiting room screening form to the question: ‘Which of the following best describes your feelings about smoking
right now?’ Patients’ readiness to quit was reassessed following strong personalised advice from the neurologists to quit.
{HADS scores: 0e7¼normal; 8e10¼borderline abnormal; 11e21¼abnormal.
29
CF, cost-free pharmacotherapy; HADS, Hospital Anxiety and Depression Scale; PO, prescription only.
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At the 26-week follow-up assessment, 62% of participants
in the PO group reported making a quit attempt
compared to 53% in the CF group. Observed differences
between the groups both for use of quit smoking medi-
cations and for compliance with the full course of
medication were not statistically signiﬁcant. Participants
in the CF group completed a mean of 6.3/7 (91%)
sessions compared to 5.5/7 (78%) sessions in the PO
group (see table 3).
DISCUSSION
To our knowledge this is the ﬁrst study to evaluate the
efﬁcacy of providing a starter kit of cost-free pharmaco-
therapy to patients at high risk of stroke who are ready to
quit smoking. Observed differences between interven-
tion groups for both the primary and secondary study
outcomes were non-signiﬁcant, and therefore a larger
trial would be required to assess intervention efﬁcacy.
This pilot study found the study methods to be feasible
and has provided previously unavailable data which will
be used to inform sample size estimates for the design of
a larger deﬁnitive trial. The study documented a much
lower eligibility and participation rate than was originally
hypothesised. The fact that only 40% of eligible smokers
enrolled in the study suggests consideration must be
given to interventions to increase patient enrolment in
future investigations.
While there have been no trials to evaluate the efﬁcacy
of providing cost-free quit smoking medications to
stroke or TIA patients, studies in the general population
have found that the provision of cost-free smoking
cessation medications increases patient motivation to
quit, quit attempts and smoking abstinence.
20e23 A
systematic review including three trials examining the
beneﬁt of covering the cost of smoking cessation treat-
ment (primarily the cost of pharmacotherapy) found
that cost-free treatment increased the odds of achieving
abstinence (OR 1.6; 95% CI 1.2 to 2.2) compared to
having smokers pay for their own treatment.
11 30 One
additional trial, completed after the meta-analysis
described above was published, found that providing
cost-free effective smoking cessation pharmacotherapies
to smokers in primary care increased the odds of quit-
ting 12 months after recruitment almost ﬁvefold (OR
4.77; 95% CI 2.0 to 11.2).
23 In the present study, 15% of
smokers screened had completed a university degree
compared to 25.5% of smokers in the general popula-
tion.
31 Moreover, only 18% of smokers screened had
insurance coverage for quit smoking medications. These
data support the hypothesis that ﬁnancial barriers may
inﬂuence decisions to use pharmacotherapy among
patients who have experienced TIA or stroke. Given the
signiﬁcant acute health beneﬁts derived from smoking
cessation among TIA and stroke patients, it would
appear that this intervention program may be of partic-
ular signiﬁcance for reducing disease burden and
improving stroke outcomes.
Our investigation showed that a large proportion of
smokers screened as part of the present study were not
ready to quit smoking in the 30 days following their visit
to the Stroke Prevention Clinic. The reported rate is
Table 2 26-Week smoking abstinence
6-Month abstinence
measure
PO group,
n/N (%)
Cost-free
group, n/N (%) OR (95% CI) p Value
Adjusted
OR (95% CI)* p Value*
Continuous abstinence 2/13 (15.4) 5/15 (33.3) 2.75 (0.43 to 17.5) 0.26 5.51 (0.44 to 69.3) 0.19
7-Day point prevalence
abstinence
3/13 (23.1) 5/15 (33.3) 1.67 (0.31 to 8.9) 0.43 2.25 (0.25 to 20.4) 0.47
Biochemically validated
7-day point prevalence
abstinence
2/13 (15.4) 4/15 (26.6) 2.00 (0.33 to 13.3) 0.40 5.95 (0.40 to 88.7) 0.20
*Adjusted for number of cigarettes smoked per day and self-efﬁcacy.
CF, cost-free pharmacotherapy; PO, prescription only.
Table 3 Compliance with medications and quit attempts
6-Month abstinence
measure
PO group,
n/N (%)
Cost-free
group, n/N (%) OR (95% CI) p Value
Adjusted
OR (95% CI)* p Value*
Quit attempts 8/13 (61.5) 8/15 (53.3) 0.71 (0.16 to 3.2) 0.66 0.72 (0.12 to 4.5) 0.72
Began using medication
prescribed
8/13 (61.5) 11/15 (73.3) 1.7 (0.35 to 8.5) 0.51 0.44 (0.03 to 5.9) 0.54
Compliance with medication
>90%
4/13 (30.7) 7/15 (46.7) 2.0 (0.42 to 9.3) 0.39 2.2 (0.35 to 14.5) 0.40
Compliance with telephone
counselling >80%
8/13 (61.5) 14/15 (93.3) 8.7 (0.9 to 88.7) 0.07 4.2 (0.32 to 58.9) 0.28
*Adjusted for number of cigarettes smoked per day and self-efﬁcacy.
CF, cost-free pharmacotherapy; PO, prescription only.
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despite the presence of a teachable moment resulting
from a health event.
11 16 This suggests that smokers
identiﬁed in the stroke prevention setting represent
a ‘hardened‘ population of smokers, that is, those with
higher levels of nicotine addiction and lack of interest in
cessation.
32 This is reﬂected by the proportion of high
risk patients who were not interested in embarking upon
a quit attempt in the next 30 days following strong
clinician advice, and the fact that more than 65% of
patients sampled reported time to ﬁrst cigarette in the
morning to be within 30 min of waking. Interestingly,
30% of the study sample had indicated on the waiting
room screening form that they were not ready to quit in
the next 30 days. However, following standardised
counselling from the clinic physician, these patients
decided to quit smoking and were randomised to the
trial. Additional research is required to better under-
stand the lack of intention among stroke and TIA
patients to make a quit attempt and how best to motivate
and/or support increased patient motivation to quit
and/or harm reduction interventions such as reduce to
quit approaches.
Very limited research has been published regarding
smoking cessation interventions among patients with
stroke or TIA. An uncontrolled prospective study exam-
ining the effects of a speciﬁc smoking cessation educa-
tion intervention after stroke found that at 3 months
after the event 43% of smokers had quit smoking
compared with the 28% of smokers previously reported
in the literature as achieving cessation after an event.
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In another study, which involved in-hospital initiation of
secondary stroke prevention therapies including
smoking cessation, 83% of those identiﬁed as smokers at
the time of the event remained smoke free at 3-month
follow-up.
3 In contrast, there was no improvement in
smoking quit rates of patients with stroke or TIA at 3-
month follow-up after a multiple risk factor modiﬁcation
intervention led by a stroke nurse specialist in a single-
blind randomised controlled trial.
34 Given the paucity of
smoking cessation trials in stroke and TIA patients, it will
be particularly important for future research to investi-
gate interventions to motivate and support cessation in
this high risk population of smokers.
There are several limitations to the present study
which should be considered in any interpretation of the
ﬁndings. Despite positive trends, the pilot study was
small and included only 28 participants, and was not able
to document a signiﬁcant effect of the intervention
compared to control. Hence, a larger trial would be
required to further explore the favourable trend docu-
mented here. In the present study all patients received
access to: (1) standardised counselling; (2) a prescrip-
tion for quit smoking medications while in clinic; and
(3) follow-up support for 26 weeks following their
scheduled quit attempt. This may be considered an
enhancement over the current ‘real world’ standard of
care experienced by stroke and TIA patients. The
inclusion of the standardised counselling supports and
pharmacotherapy may have increased the quit rates
observed in both intervention groups. As the study
involved the recruitment of patients from a single stroke
prevention clinic, study ﬁndings may not be general-
isable to the broader population of stroke and TIA
patients in other settings. Only 40% of eligible patients
screened consented to participate. Finally, this pilot
study provided patients in the CF group with a 4-week
supply of pharmacotherapy free of cost. A full course of
treatment is typically 10e12 weeks. Extending the avail-
ability of the cost-free pharmacotherapy might have
further enhanced study outcomes.
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